AR and triple-negative breast carcinoma: Since Lehmann et al. reported that the luminal AR subtype, which was characterized by high expression of AR, accounted for a part of the triple-negative breast cancers [26], the AR signal pathway has attracted attention for its possibility as targeted therapy.